Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Psychiatry
Published in: BMC Psychiatry 1/2021

Open Access 01-12-2021 | Mood Disorders | Study protocol

Personalized ESM monitoring and feedback to support psychological treatment for depression: a pragmatic randomized controlled trial (Therap-i)

Authors: H. Riese, L. von Klipstein, R. A. Schoevers, D. C. van der Veen, M. N. Servaas

Published in: BMC Psychiatry | Issue 1/2021

Login to get access

Abstract

Background

Major depressive disorder (MDD) is a highly prevalent mental disorder with large disease burden, high levels of relapse or persistence, and overall suboptimal outcomes of protocolized pharmacological and psychotherapeutic treatments. There is an urgent need to improve treatment effectiveness, possibly through systematic treatment personalization. In psychotherapeutic treatments this can be achieved by case conceptualization. To support this process, we developed the Therap-i module, which consists of personalized Experienced Sampling Methodology (ESM) and feedback. The Therap-i module is integrated into outpatient psychotherapeutic treatment as usual (TAU) for depression. The study aim is to investigate the efficacy of the Therap-i module in decreasing symptomatology in unresponsive or relapsing patients diagnosed with MDD. We hypothesize that the Therap-i module will contribute to TAU by i) decreasing depressive symptoms, and ii) improving general functioning, therapeutic working alliance, and illness perception. This paper provides details of the study rationale, aims, procedures, and a discussion on potential pitfalls and promises of the module.

Methods

Patients diagnosed with MDD (n = 100) will enrol in a pragmatic two-armed randomized controlled trial. Randomization is stratified according to the patient’s treatment resistance level assessed with the Dutch Method for quantification of Treatment Resistance in Depression (DM-TRD). All fill-out the Inventory of Depressive Symptomatology Self Report (IDS-SR), Outcome Questionnaire (OQ-45), Illness Perception Questionnaire Mental Health (IPQ-MH), and Work Alliance Inventory Self Report (WAI-SR). In the intervention arm, through close collaboration between patient, clinician, and researcher, a personalized ESM diary is developed based on the patient’s case conceptualization. During the ESM monitoring period (8 weeks, 5 assessments/day), patients receive feedback three times, which is discussed among the abovementioned three parties. Both patients and clinicians will evaluate the Therap-i module.

Results

Data collection is ongoing.

Discussion

This is the first study in which personalized ESM and feedback is integrated in outpatient psychotherapeutic TAU for depression. The labour intensive procedure and methodological pitfalls are anticipated challenges and were taken into account when designing the study. When hypotheses are confirmed, the Therap-i module may advance treatment for depression by providing insights into personalized patterns driving or perpetuating depressive complaints.

Trial registration

Trial NL7190 (NTR7381), registered prospectively 03-08-2018.
Appendix
Available only for authorised users
Footnotes
1
To meet this challenge, our group is currently developing the PErsonalized Treatment by Real-time Assessment (PETRA, petrapsy.nl) tool.
 
Literature
1.
Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jonsson B, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21(9):655–79.PubMedCrossRef
2.
Olesen J, Gustavsson A, Svensson M, Wittchen HU, Jonsson B. CDBE2010 study group, et al. the economic cost of brain disorders in Europe. Eur J Neurol. 2012;19(1):155–62.PubMedCrossRef
3.
Kessler RC, De Jonge P, Shahly V, Van Loo HM, Wang PSE, Wilcox MA. Epidemiology of depression. In: Gotlib IH, Hammen CL, editors. Handbook of depression. 3rd ed. New York, NY, US: Guilford Press; 2014. p. 7–24.
4.
Hofmann SG, Asnaani A, Vonk IJJ, Sawyer AT, Fang A. The efficacy of cognitive behavioral therapy: a review of meta-analyses. Cognit Ther Res. 2012;36(5):427–40.PubMedPubMedCentralCrossRef
5.
Kuyken W, Padesky CA, Dudley R. Collaborative case conceptualization: working effectively with clients in cognitive-behavioral therapy. New York: Guilford Press; 2009.
6.
Johnstone L, Dallos R. Introduction to formulation. In: Johnstone L, Dallos R, editors. Formulation in psychology and psychotherapy. 2nd ed. New York: Routledge; 2014.
7.
Sperry L, Gudeman JE, Blackwell B, Faulkner LR. Psychiatric case formulations. Arlington: American Psychiatric Association; 1992.
8.
Flitcroft A, James IA, Freeston M, Wood-Mitchell A. Determining what is important in a good formulation. J Cogn Psychother. 2007;35(3):325–33.CrossRef
9.
Persons JB, Mooney KA, Padesky CA. Interrater relability of cognitive-behavioral case formulations. Cognit Ther Res. 1995;19(1):21–34.CrossRef
10.
Myin-Germeys I, Kasanova Z, Vaessen T, Vachon H, Kirtley O, Viechtbauer W, et al. Experience sampling methodology in mental health research: new insights and technical developments. World Psychiatry. 2018;17(2):123–32.PubMedPubMedCentralCrossRef
11.
Wichers M. The dynamic nature of depression: a new micro-level perspective of mental disorder that meets current challenges. Psychol Med. 2014;44(7):1349–60.PubMedCrossRef
12.
Piccirillo ML, Beck ED, Rodebaugh TL. A clinician's primer for idiographic reserach: considerations and recommandations. Behav Ther. 2019;50(5):938–51.PubMedCrossRef
13.
Stone A, Shiffman S. Ecological momentary assessment (EMA) in behavioral medicine. Ann Behav Med. 1994;15:199–202.CrossRef
14.
Mehl MR, Conner TS. Handbook of research methods for studying daily life. New York: The Guilford Press; 2012.
15.
Bos FM, Snippe E, Bruggeman R, Wichers M, van der Krieke L. Insights of patients and clinicians on the promise of the experience sampling method for psychiatric care. Psychiatr Serv. 2019;70:983–91.PubMedCrossRef
16.
Kroeze R, Van der Veen DC, Servaas MN, Bastiaansen JA, Oude Voshaar R, Borsboom D, et al. Personalized feedback on symptom dynamics of psychopathology: a proof-of-principle study. JPOR. 2017;3(1):1–10.PubMedCrossRefPubMedCentral
17.
von Klipstein L, Riese H, van der Veen DC, Servaas MN, Schoevers RA. Using person-specific networks in psychotherapy: challenges, limitations, and how we could use them anyway. BMC Med. 2020;18(1):345.CrossRef
18.
Bringmann LF, Vissers N, Wichers M, Geschwind N, Kuppens P, Peeters F, et al. A network approach to psychopathology: new insights into clinical longitudinal data. PLoS One. 2013;8(4):e60188.PubMedPubMedCentralCrossRef
19.
Groot PC. Patients can diagnose too: how continuous self-assessment aids diagnosis of, and recovery from, depression. J Ment Health. 2010;19(4):352–62.PubMedCrossRef
20.
21.
Kramer I, Simons CJ, Hartmann JA, Menne-Lothmann C, Viechtbauer W, Peeters F, et al. A therapeutic application of the experience sampling method in the treatment of depression: a randomized controlled trial. World Psychiatry. 2014;13(1):68–77.PubMedPubMedCentralCrossRef
22.
Bastiaansen JA, Meurs M, Stelwagen R, Wunderink L, Schoevers RA, Wichers M, et al. Self-monitoring and personalized feedback based on the experiencing sampling method as a tool to boost depression treatment: a protocol of a pragmatic randomized controlled trial (ZELF-i). BMC Psychiatry. 2018;18(1):276 –018-1847-z.PubMedPubMedCentralCrossRef
23.
Bastiaansen JA, Ornee DA, Meurs M, Oldehinkel AJ. An evaluation of the efficacy of two add-on ecological momentary intervention modules for depression in a pragmatic randomized controlled trial (ZELF-i). Psychol Med. 2020;14:1–10.
24.
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap): a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–81.CrossRefPubMed
25.
Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019;95:103208.PubMedPubMedCentralCrossRef
26.
Nienhuis FJ, van de Willige G, Rijnders CA, de Jonge P, Wiersma D. Validity of a short clinical interview for psychiatric diagnosis: the mini-SCAN. Br J Psychiatry. 2010;196(1):64–8.PubMedCrossRef
27.
Peeters FP, Ruhe HG, Wichers M, Abidi L, Kaub K, van der Lande HJ, et al. The Dutch measure for quantification of treatment resistance in depression (DM-TRD): an extension of the Maudsley staging method. J Affect Disord. 2016;205:365–71.PubMedCrossRef
28.
de Jong P, Berg IK. Interviewing for solutions. 4th edition ed. Cengage Learning Company: Wadsworth; 2012.
29.
Bos FM, von Klipstein L, Emerencia AC, Veermans E, Wichers M, Riese H. PErsonalized Treatment Real-time Assessment (PETRA): A flexible interface for personalized diaries0020in psychiatry. 2021; Manuscript in preparation.
30.
van Genugten CR, Schuurmans J, Lamers F, Riese H, Penninx BW, Schoevers RA, et al. Experienced burden of and adherence to smartphone-based ecological momentary assessment in persons with affective disorders. J Clin Med. 2020;9(2):322.PubMedCentralCrossRef
31.
Sytema S, Van der Krieke L. Routine outcome monitoring: a tool to improve the quality of mental health care? In: Thornicroft G, Ruggeri M, Goldberg D, editors. Improving mental health care: the global challenge. 1st ed. Chichester: Wiley; 2013. p. 246–63.CrossRef
32.
33.
34.
Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH. The inventory of depressive symptomatology (IDS): psychometric properties. Psychol Med. 1996;26(3):477–86.PubMedCrossRef
35.
Nolen WN, Dingemans PMAJ. Meetinstrumenten bij stemmingsstoornissen (instruments for measuring mood disorders). Tijdschrift voor Psychiatrie. 2004;46:681–6.
36.
Schulte-van Maaren YW, Carlier IV, Zitman FG, van Hemert AM, de Waal MW, van der Does AJ, et al. Reference values for major depression questionnaires: the Leiden routine outcome monitoring study. J Affect Disord. 2013;149(1–3):342–9.PubMedCrossRef
37.
Lambert MJ, Burlingame GM, Umphress V, Hansen NB, Vermeersch DA, Clouse GC, et al. The reliability and validity of the outcome questionnaire. Clin Psychol Psychother. 1996;3:249–58.CrossRef
38.
de Jong K, Nugter MA, Polak MG, Wagenborg JEA, Spinhoven P, Heiser WJ. The outcome questionnaire (OQ-45) in a Dutch population: a cross-cultural validation. Clin Psychol Psychother. 2007;14(4):288–301.CrossRef
39.
Horvath AO, Greenberg LS. Development and validation of the working Alliance inventory. J Couns Psychol. 1989;36(2):223–33.CrossRef
40.
Vervaeke G, Vertommen H. De Werkalliantievragenlijst (WAV). Gedragstherapie. 1996;29:139–44.
41.
Witteman C, Bolks L, Hutschemaekers G. Development of the illness perception questionnaire mental health. J Ment Health. 2011;20(2):115–25.PubMedCrossRef
42.
Bagby RM, Parker JD, Taylor GJ. The twenty-item Toronto alexithymia scale--I. item selection and cross-validation of the factor structure. J Psychosom Res. 1994;38(1):23–32.PubMedCrossRef
43.
Bagby RM, Taylor GJ, Parker JD. The twenty-item Toronto alexithymia scale--II. Convergent, discriminant, and concurrent validity. J Psychosom Res. 1994;38(1):33–40.PubMedCrossRef
44.
Taylor GJ, Bagby RM, Parker JD. The 20-item Toronto alexithymia scale. IV. Reliability and factorial validity in different languages and cultures. J Psychosom Res. 2003;55(3):277–83.PubMedCrossRef
45.
van der Does W. Cognitive reactivity to sad mood: structure and validity of a new measure. Behav Res Ther. 2002;40(1):105–20.PubMedCrossRef
46.
Solis E, Antypa N, Conijn JM, Kelderman H, Van der Does W. Psychometric properties of the Leiden index of depression sensitivity (LEIDS). Psychol Assess. 2017;29(2):158–71.PubMedCrossRef
47.
Oldehinkel AJ, Rosmalen JGM, Buitelaar JK, Hoek HW, Ormel J, Raven D, et al. Cohort profile update: The TRacking Adolescents' Individual Lives Survey (TRAILS). Int J Epidemiol. 2015;44(1):76–76n. https://​doi.​org/​10.​1093/​ije/​dyu225. PMID: 25431468. PMCID: PMC4339762.
48.
De Graaf LE, Roelofs J, Huibers MJ. Measuring dysfunctional attitudes in the general population: the dysfunctional attitude scale (form a) revised. Cognit Ther Res. 2009;33(4):345–55.PubMedPubMedCentralCrossRef
49.
Thombs BD, Bernstein DP, Lobbestael J, Arntz A. A validation study of the Dutch childhood trauma questionnaire-short form: factor structure, reliability, and known-groups validity. Child Abuse Negl. 2009;33(8):518–23.PubMedCrossRef
50.
van Grieken RA, Kirkenier AC, Koeter MW, Nabitz UW, Schene AH. Patients' perspective on self-management in the recovery from depression. Health Expect. 2015;18(5):1339–48.PubMedCrossRef
51.
Brugha T, Bebbington P, Tennant C, Hurry J. The list of threatening experiences: a subset of 12 life event categories with considerable long-term contextual threat. Psychol Med. 1985;15(1):189–94.PubMedCrossRef
52.
Spinhoven P, Elzinga BM, Hovens JG, Roelofs K, van Oppen P, Zitman FG, et al. Positive and negative life events and personality traits in predicting course of depression and anxiety. Acta Psychiatr Scand. 2011;124(6):462–73.PubMedCrossRef
53.
Abdel-Khalek AM. Measuring happiness with a single-item scale. Soc Behav Pers. 2006;34(2):139–50.CrossRef
54.
Bos EH, Snippe E, de Jonge P, Jeronimus BF. Preserving subjective wellbeing in the face of psychopathology: buffering effects of personal strengths and resources. PLoS One. 2016;11(3):e0150867.PubMedPubMedCentralCrossRef
55.
Faul F, Erdfelder E, Lang AG, Buchner A. G*power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39(2):175–91.CrossRefPubMed
56.
Dierckx de Casterle B, Gastmans C, Bryon E, Denier Y. QUAGOL: A guide for qualitative data analysis. In J Nurs Stud. 2012;49(3):360–71.CrossRef
57.
Lambert MJ, Whipple JL, Kleinstäuber M. Collecting and delivering progress feedback: a meta-analysis of routine outcome monitoring. Psychotherapy. 2018;55(4):520–37.PubMedCrossRef
58.
Spinhoven P, Cuijpers P, Hollon S. Cognitive-behavioural therapy and personalized treatment: an introduction to the special issue. Behav Res Ther. 2020;129:103595.PubMedCrossRef
59.
van Os J, Guloksuz S, Vijn TW, Hafkenscheid A, Delespaul P. The evidence-based group-level symptom-reduction model as the organizing principle for mental health care: time for change? World Psychiatry. 2019;18(1):88–96.PubMedPubMedCentralCrossRef
Metadata
Title
Personalized ESM monitoring and feedback to support psychological treatment for depression: a pragmatic randomized controlled trial (Therap-i)
Authors
H. Riese
L. von Klipstein
R. A. Schoevers
D. C. van der Veen
M. N. Servaas
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Psychiatry / Issue 1/2021
Electronic ISSN: 1471-244X
DOI
https://doi.org/10.1186/s12888-021-03123-3

Other articles of this Issue 1/2021

BMC Psychiatry 1/2021 Go to the issue

Research

The effect of depressive symptoms on pain in a substance-using population with persistent pain: a cross-sectional cohort study

Research

Development and validity of the Value-based Stigma Inventory (VASI): a value-sensitive questionnaire for the assessment of mental health stigma

Research article

Mental health screening amongst police officers: factors associated with under-reporting of symptoms

Research

Trends in antipsychotic prescribing for approved and unapproved indications to Medicaid-enrolled youth in Philadelphia, Pennsylvania between 2014 and 2018

Research

Clinical characteristic of prodromal symptoms between bipolar I and II disorder among Chinese patients: a retrospective study

Correction

Correction to: Symptoms of anxiety disorders in Iranian adolescents with hearing loss during the COVID-19 pandemic